GZA Ziekenhuizen - Campus Sint-Augustinus

Antwerp 2610

1 studies enrolling now · 3 studies all time

What they study most

Breast Cancer, HER2 Positive Breast Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Locally Advanced or Unresectable Metastatic Breast Cancer, Non-small Cell Lung Cancer (NSCLC), Pancreatic Adenocarcinoma, Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Stage IV Breast Cancer, Triple Negative Breast Cancer (TNBC)

Studies at this site

• Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors — Recruiting now
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early